Yıl: 2022 Cilt: 19 Sayı: 3 Sayfa Aralığı: 336 - 342 Metin Dili: İngilizce DOI: 10.4274/tjps.galenos.2021.41514 İndeks Tarihi: 05-07-2022

Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain

Öz:
Objectives: Drugs that inhibit the reuptake of serotonin, norepinephrine, and/or dopamine are widely used for treating depressive disorders and have emerged as effective drugs for neuropathic pain. They have no substantial anti-nociceptive effects but are considered, with gabapentin/ pregabalin, first-line drugs for neuropathic pain. Materials and Methods: In this study, three different antidepressant agents were used in different doses to investigate their anti-hyperalgesic effects in rat models of neuropathic pain using hot plate and tail flick methods. They have different mechanisms of action; vilazodone hydrochloride is a selective serotonin inhibitor and a 5-HT1A partial agonist; talsupram hydrochloride is a selective noradrenaline inhibitor, and it has a high affinity for noradrenaline transporter (NET), whereas indatraline hydrochloride is a triple reuptake inhibitor that inhibits transporters for 5-HT (SERT), dopamine (DAT), and NET. Results: All the drugs used in the experiment were found to have an anti-hyperalgesic effect in both tests compared to the sham group. When antihyperalgesic effects of the three agents were compared to each other, it was found that talsupram hydrochloride was significantly more effective than the two other drugs in hot plate test. However, there was no statistically significant difference in the tail flick test. Indatraline hydrochloride was more effective than vilazodone hydrochloride at the same doses in the tail flick test. Conclusion: Our data suggest that three drugs are effective analgesics in rat models of neuropathic pain and inhibition of noradrenaline reuptake represents the cornerstone of analgesic mechanisms of effective antidepressants.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice ASC, Treede RD. A new definition of neuropathic pain. Pain. 2011;152:2204-2205.
  • 2. Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington (DC): National Academies Press (US); 2011.
  • 3. Leadley RM, Armstrong N, Lee YC, Allen A, Kleijnen J. Chronic diseases in the European Union: the prevalence and health cost implications of chronic pain. J Pain Palliat Care Pharmacother. 2012;26:310-325.
  • 4. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7:281-289.
  • 5. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136:380-387.
  • 6. Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet. 2007;369:946-955.
  • 7. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-173.
  • 8. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016;65:1- 49. Erratum in: MMWR Recomm Rep. 2016;65:295.
  • 9. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e1188.
  • 10. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573-581.
  • 11. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice ASC, Stacey BR, Treede RD, Turk DC, Wallace MS. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237-251.
  • 12. Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16:1347-1368.
  • 13. Bee L, Dickenson A. Descending modulation of pain. In: Malcangio M, editor. Synaptic plasticity in pain. New York: Springer Verlag; 2009. pp. 307-335.
  • 14. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain. 1990;43:205-218.
  • 15. Malmberg AB, Basbaum AI. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain. 1998;76:215-222.
  • 16. Kanaan SA, Saadé NE, Haddad JJ, Abdelnoor AM, Atweh SF, Jabbur SJ, Safieh-Garabedian B. Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain. Pain. 1996;66:373-379.
  • 17. Ramabadran K, Bansinath M, Turndorf H, Puig MM. The hyperalgesic effect of naloxone is attenuated in streptozotocin-diabetic mice. Psychopharmacology (Berl). 1989;97:169-174.
  • 18. Bannon AW, Malmberg AB. Models of nociception: hot-plate, tail-flick, and formalin tests in rodents. Curr Protoc Neurosci. 2007;8:8.9.
  • 19. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155:654-662. Erratum in: Pain. 2014;155:1907.
  • 20. Guevara-López U, Covarrubias-Gómez A, García-Ramos G, Hernández- Jiménez S; Grupo de Consenso para el Manejo del Dolor Neuropático. Parámetros de práctica para el manejo del dolor neuropático [Practice guidelines for neuropathic pain management]. Rev Invest Clin. 2006;58:126-138.
  • 21. Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc. 2015;90:532-545.
  • 22. Mayoral V, Pérez-Hernández C, Muro I, Leal A, Villoria J, Esquivias A. Diagnostic accuracy of an identification tool for localized neuropathic pain based on the IASP criteria. Curr Med Res Opin. 2018;34:1465-1473.
  • 23. Meyer-Rosberg K, Burckhardt CS, Huizar K, Kvarnström A, Nordfors LO, Kristofferson A. A comparison of the SF-36 and Nottingham Health Profile in patients with chronic neuropathic pain. Eur J Pain. 2001;5:391- 403.
  • 24. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Chronic painassociated depression: antecedent or consequence of chronic pain? A review. Clin J Pain. 1997;13:116-137.
  • 25. Sudoh Y, Cahoon EE, Gerner P, Wang GK. Tricyclic antidepressants as long-acting local anesthetics. Pain. 2003;103:49-55.
  • 26. Vadivelu N, Kai A, Maslin B, Kodumudi G, Legler A, Berger JM. Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Ther Clin Risk Manag. 2015;11:95-105.
  • 27. Attal N. Pharmacological treatments of neuropathic pain: the latest recommendations. Rev Neurol (Paris). 2019;175:46-50.
  • 28. Hache G, Guiard BP, Nguyen TH, Quesseveur G, Gardier AM, Peters D, Munro G, Coudoré F. Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain. Eur J Pain. 2015;19:322-333.
  • 29. Fishbain DA, Detke MJ, Wernicke J, Chappell AS, Kajdasz DK. The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder. Curr Med Res Opin. 2008;24:3105-3115.
  • 30. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, Williams DA, Mease PJ, McLean SA, Clauw DJ. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32:1975- 1985.
  • 31. Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med. 2010;11:180-194.
  • 32. Gray AM, Pache DM, Sewell RD. Do alpha2-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds? Eur J Pharmacol. 1999;378:161-168.
  • 33. Bardin L. The complex role of serotonin and 5-HT receptors in chronic pain. Behav Pharmacol. 2011;22:390-404.
  • 34. Viguier F, Michot B, Hamon M, Bourgoin S. Multiple roles of serotonin in pain control mechanisms-implications of 5-HT7 and other 5-HT receptor types. Eur J Pharmacol. 2013;716:8-16.
  • 35. Yoshimura M, Furue H. Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotonergic systems in the spinal cord. J Pharmacol Sci. 2006;101:107-117.
  • 36. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355- 474.
  • 37. Jung AC, Staiger T, Sullivan M. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med. 1997;12:384-389.
  • 38. Irwin S, Houde RW, Bennett DR, Hendershot LC, Seevers MH. The effects of morphine methadone and meperidine on some reflex responses of spinal animals to nociceptive stimulation. J Pharmacol Exp Ther. 1951;101:132-143.
  • 39. Giglio CA, Defino HL, da-Silva CA, de-Souza AS, Del Bel EA. Behavioral and physiological methods for early quantitative assessment of spinal cord injury and prognosis in rats. Braz J Med Biol Res. 2006;39:1613- 1623.
  • 40. Smith AJ. The analgesic effects of selective serotonin reuptake inhibitors. J Psychopharmacol. 1998;12:407-413.
APA HACISÜLEYMAN L, Saraç B, Joha Z (2022). Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain. , 336 - 342. 10.4274/tjps.galenos.2021.41514
Chicago HACISÜLEYMAN LEVENT,Saraç Bülent,Joha Zıad Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain. (2022): 336 - 342. 10.4274/tjps.galenos.2021.41514
MLA HACISÜLEYMAN LEVENT,Saraç Bülent,Joha Zıad Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain. , 2022, ss.336 - 342. 10.4274/tjps.galenos.2021.41514
AMA HACISÜLEYMAN L,Saraç B,Joha Z Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain. . 2022; 336 - 342. 10.4274/tjps.galenos.2021.41514
Vancouver HACISÜLEYMAN L,Saraç B,Joha Z Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain. . 2022; 336 - 342. 10.4274/tjps.galenos.2021.41514
IEEE HACISÜLEYMAN L,Saraç B,Joha Z "Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain." , ss.336 - 342, 2022. 10.4274/tjps.galenos.2021.41514
ISNAD HACISÜLEYMAN, LEVENT vd. "Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain". (2022), 336-342. https://doi.org/10.4274/tjps.galenos.2021.41514
APA HACISÜLEYMAN L, Saraç B, Joha Z (2022). Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain. Turkish Journal of Pharmaceutical Sciences, 19(3), 336 - 342. 10.4274/tjps.galenos.2021.41514
Chicago HACISÜLEYMAN LEVENT,Saraç Bülent,Joha Zıad Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain. Turkish Journal of Pharmaceutical Sciences 19, no.3 (2022): 336 - 342. 10.4274/tjps.galenos.2021.41514
MLA HACISÜLEYMAN LEVENT,Saraç Bülent,Joha Zıad Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain. Turkish Journal of Pharmaceutical Sciences, vol.19, no.3, 2022, ss.336 - 342. 10.4274/tjps.galenos.2021.41514
AMA HACISÜLEYMAN L,Saraç B,Joha Z Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain. Turkish Journal of Pharmaceutical Sciences. 2022; 19(3): 336 - 342. 10.4274/tjps.galenos.2021.41514
Vancouver HACISÜLEYMAN L,Saraç B,Joha Z Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain. Turkish Journal of Pharmaceutical Sciences. 2022; 19(3): 336 - 342. 10.4274/tjps.galenos.2021.41514
IEEE HACISÜLEYMAN L,Saraç B,Joha Z "Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain." Turkish Journal of Pharmaceutical Sciences, 19, ss.336 - 342, 2022. 10.4274/tjps.galenos.2021.41514
ISNAD HACISÜLEYMAN, LEVENT vd. "Analgesic Effects of Vilazodone, Indatraline, and Talsupram in a Rat Model of Neuropathic Pain". Turkish Journal of Pharmaceutical Sciences 19/3 (2022), 336-342. https://doi.org/10.4274/tjps.galenos.2021.41514